AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00679965
Drug: AN2690, 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 90 days and 3 x weekly for 90 days
Trial: NCT00679965
Drug: AN2690, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 90 days and 3 x weekly for 90 days
Trial: NCT00679965
Drug: AN2690, 7.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 90 days and 3 x weekly for 90 days
Trial: NCT00679965
Drug: AN2690 Solution Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 90 days and 3x weekly for 90 days
Trial: NCT02299999
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: m-TOR
Trial: NCT02299999
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: EGFR
Trial: NCT02299999
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: AKT
Trial: NCT02299999
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: HER2, EGFR
Trial: NCT02299999
Drug: Anthracyclines
RxNorm normalized name: Anthracyclines and related substances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA intercalation
Trial: NCT02299999
Drug: Taxanes
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: mitotic tubulin and microtubules
Trial: NCT02299999
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alkylating agents
Trial: NCT02299999
Drug: DNA intercalators
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA intercalators
Trial: NCT02299999
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DNA intercalators
Trial: NCT02299999
Drug: vinca alkaloids
RxNorm normalized name: Vinca alkaloids and analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: mitotic tubulin and microtubules
Trial: NCT00440557
Drug: Epoetin alfa 3 times weekly /once weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
Trial: NCT01572948
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
Trial: NCT03603314
Drug: SENS-401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
Trial: NCT03603314
Drug: SENS-401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
Trial: NCT00183807
Drug: irinotecan, cisplatin, celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02267083
Drug: GPX-150 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
Trial: NCT00422747
Drug: beclomethasondipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 100 ug dd for two months, via aerochamber
Trial: NCT02114268
Drug: MEDI8897 Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
Trial: NCT02114268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo on Day 1.
Trial: NCT01941966
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
Trial: NCT00716248
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate 6 mg or more per week
Trial: NCT02504359
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00944203
Drug: Ipomea pes-caprae ointment
RxNorm normalized name: IPOMOEA PES-CAPRAE FLOWERING TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
Trial: NCT00196755
Drug: Calcium acetate (PhosLo® )
RxNorm normalized name: calcium acetate Oral Capsule [Phoslo]
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium acetate three times per day with each meal
Trial: NCT01218113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 3 doses according to protocol schedule
Trial: NCT00896246
Drug: Klean-Prep®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four litres of solution administered orally as a divided dose.
Trial: NCT00896246
Drug: Moviprep®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two litres of solution administered orally as a divided dose
Trial: NCT03855332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overencapsulated placebo
Trial: NCT00874237
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato placebo single dose
Trial: NCT00874237
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo similar in appearance to moxifloxacin 400 mg
Trial: NCT02683837
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03811028
Drug: SOBI003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly i.v. infusion
Trial: NCT01639768
Drug: SUBLIVAC FIX Birch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages to placebo
Trial: NCT01988909
Drug: WR 279,396
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin + Gentamicin Topical Cream
Trial: NCT01244269
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind gelatin capsule three times daily for a total of 7 doses.
Trial: NCT01244269
Drug: Placebo 20
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind gelatin capsule three times daily for a total of 7 doses
Trial: NCT01542125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubes were visually identical to the Liposomal Lidocaine tubes.
Trial: NCT00951223
Drug: Infergen® (Interferon alfacon-1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
Trial: NCT04109183
Drug: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Trial: NCT04961268
Drug: Ibuprofen 600Mg Tab
RxNorm normalized name: IBUPROFEN 600MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Trial: NCT04961268
Drug: ibuprofen 600 mg/acetaminophen 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Trial: NCT04961268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Trial: NCT04487392
Drug: Estrogen vaginal cream group (group A)
RxNorm normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
Trial: NCT03854929
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis.
Trial: NCT03908320
Drug: NRT Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT patch is provided
Trial: NCT03111485
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule taken at bedtime
Trial: NCT04689204
Drug: CTA30X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTA30X cell injection by intravenous infusion
Trial: NCT01461850
Drug: Neoadjuvant chemotherapy + Interval Debulking Surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
Trial: NCT02492477
Drug: blocking with Medunasal®-Heparinblock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
Trial: NCT01624064
Drug: Calcium Supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 2.5-20 mg/day
Trial: NCT01987960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, tablets, orally
Trial: NCT00580372
Drug: High-Dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1
Trial: NCT02625454
Drug: Intravenous Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Acetaminophen q 6 hours, given intravenously
Trial: NCT02625454
Drug: Oral Acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Acetaminophen q 6 hours given orally
Trial: NCT02107300
Drug: NeutraSal
RxNorm normalized name: NeutraSal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
Trial: NCT02569073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo--no drug
Trial: NCT03079271
Drug: Lacrisert, 5 Mg Ophthalmic Insert
RxNorm normalized name: Lacrisert, 5 mg ophthalmic insert
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01712620
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
Trial: NCT01712620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
Trial: NCT00745823
Drug: TRUVADA™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
Trial: NCT01962337
Drug: FPA008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT01962337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT03613545
Drug: probiotics, antibiotics or antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs such as probiotics, antibiotics, antidepressants
Trial: NCT02036697
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mcg
Trial: NCT04873011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of water will be infused into the stomach in a randomized, double-blinded fashion
Trial: NCT00513110
Drug: Caffeine infusion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
Trial: NCT00513110
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin 2ng/kg combined with saline infusion (0.9%)
Trial: NCT02923388
Drug: Tablet Pyridoxine hydrochloride
RxNorm normalized name: pyridoxine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
Trial: NCT02923388
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill orally thrice daily for 5 weeks
Trial: NCT02781727
Drug: Once weekly subcutaneous injection of TransCon hGH
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly subcutaneous injection
Trial: NCT02781727
Drug: Once daily subcutaneous injection of Genotropin
RxNorm normalized name: Genotropin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily subcutaneous injection
Trial: NCT02282150
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
Trial: NCT04759885
Drug: Phase II: NTC015 low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Trial: NCT04759885
Drug: Phase II: NTC015 medium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Trial: NCT04759885
Drug: Phase II: NTC015 high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Trial: NCT04759885
Drug: Phase III: NTC015 selected dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Trial: NCT03435081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01122147
Drug: chamomilla tincture mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal
Trial: NCT01122147
Drug: placebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
Trial: NCT02242630
Drug: Methylprednisolone, 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compared with intrabursal triamcinolone
Trial: NCT00717197
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
Trial: NCT01977820
Drug: Sapropterin
RxNorm normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
Trial: NCT01977820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
Trial: NCT00683202
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
Trial: NCT00683202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
Trial: NCT02242630
Drug: Methylprednisolone, 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compared with intrabursal triamcinolone
Trial: NCT03001960
Drug: Preloading before TAVI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preloading with Aspirin and Clopidogrel before TAVI
Trial: NCT03001960
Drug: Postloading after TAVI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postloading with Aspirin and Clopidogrel after TAVI
Trial: NCT01356849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
Trial: NCT04214860
Drug: APR-246
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APR-246 4.5 g/day
Trial: NCT00635167
Drug: Contrast Enhanced-Transrectal Ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline \[Visit 2\]); week 5 (middle of treatment \[Visit 3\]); week 10 (end of treatment \[Visit 4\]); week 18 (2 months after end of EBRT \[Visit 5\]); week 26 (4 months after end of EBRT \[Visit 6\]); and week 36 (6 months after end of EBRT \[Visit 7\]).
Trial: NCT02262117
Drug: specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
Trial: NCT04410731
Drug: Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy
RxNorm normalized name: CANINE ALLOGENEIC FREEZE-DRIED PLATELET-RICH PLASMA 400000000 in 1 mL INTRA-ARTICULAR INJECTION, POWDER, FOR SUSPENSION [PrecisePRP Canine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bilateral intra-articular injection of manufactured cell cultured expanded allogeneic BM-MSCs for painful lumbar facet joint arthropathy
Trial: NCT02067195
Drug: Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hydration for patients without chronic kidney disease(CrCl\<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
Trial: NCT01874756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 placebo capsules daily for 8 weeks
Trial: NCT01874756
Drug: LY500307 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
Trial: NCT04078568
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.